… -S IgG. Anti-S IgG antibody titers after vaccination were lower in participants with CID
receiving glucocorticoids (n = 17) than in those not receiving them; the geometric mean of anti-S …

Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in
2012, but the evidence for these recommendations was only of indirect nature. These …

… Gensler has received consulting fees, speaking fees, and/or honoraria from AbbVie, UCB,
and Amgen (less than $10,000 each) and research grants from Celgene and AbbVie. Dr. …

Objective To update evidence‐based recommendations for the treatment of patients with
ankylosing spondylitis ( AS ) and nonradiographic axial spondyloarthritis (SpA). Methods We …

… Gensler has received consulting fees and/or honoraria from UCB and AbbVie for Advisory
… Haroon and Gensler had full access to all of the data in the study and take responsibility for …

Objective To evaluate the efficacy and safety of ustekinumab in 3 randomized, placebo‐controlled
studies in patients with axial spondyloarthritis (SpA). Studies 1 and 2 included patients …

… Serum anti-SARS-CoV-2 spike (S) IgG + binding, neutralizing antibody titers, and circulating
S… We did not observe lower anti-S IgG titers in participants taking a combination of TNFi with …

Ankylosing spondylitis (AS) is a common, highly heritable, inflammatory arthritis for which
HLA-B*27 is the major genetic risk factor, although its role in the aetiology of AS remains …

Objective To assess the efficacy/safety of tofacitinib in adult patients with active ankylosing
spondylitis (AS). Methods This phase III, randomised, double-blind, placebo-controlled study …

Background Ixekizumab, a high-affinity interleukin-17A (IL-17A) monoclonal antibody, has
previously shown efficacy in radiographic axial spondyloarthritis (also known as ankylosing …